6 days ago
US FDA extends review of GSK's blood cancer drug
July 23 (Reuters) - The U.S. Food and Drug Administration has extended its review of GSK's (GSK.L), opens new tab blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
The health regulator has set an action date of October 23 which provides the FDA with time to review additional information provided in support of the application.
